Shanghai Ark Biopharmaceutical
CompanyChina
Shanghai Ark Biopharmaceutical develops one asset, in phase 2 (AK0406 in influenza prevention). Mostly other; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Long-acting antiviral drug-Fc conjugate intended to prevent influenza.
Phase 2, Other, influenza prevention
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1
- Similar companies1